MDS and MPN
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Next Questions in MDS
FEATURING
Guillermo Garcia-Manero
- 16 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Treatment Options for MDS With Ring Sideroblasts: A Case-Based Discussion
FEATURING
Mustafa Çetiner
- 12 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Optimizing the Management of Low-Risk MDS
FEATURING
Uwe Platzbecker
- 22 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Current State-of-the-Art in MDS
FEATURING
Moshe Mittelman
- 14 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Advances and Unmet Needs in MPN Treatment
FEATURING
Daniela Cilloni
- 82 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in MPNs: IFN-α is the Optimal 1L Treatment for Young PV Patients
FEATURING
Rajko Kusec
- 13 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in MPNs: Hydroxyurea is the Optimal 1L Treatment for Young PV Patients
FEATURING
Emre Eşkazan
- 21 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Updates in the Prognosis and Treatment of Myelofibrosis
FEATURING
Selami Koçak Toprak
- 32 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CBL Mutated MPNs: Overview and Case Discussion
FEATURING
Alessandro Lucchesi
- 49 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Key Biological and Clinical Developments in MPNs
FEATURING
Tariq Mughal
- 113 views
- February 16, 2024